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Abstract
Background: Low-grade incomplete post-dexamethasone cortisol suppression in patients with adrenal incidentalomas 
– recently defined as possible autonomous cortisol secretion (pACS) – has been associated with increased 
cardiovascular events and mortality. However, prospective studies documenting cardiac abnormalities in these patients 
are lacking.
Subjects and methods: Between July 2016 and September 2017, 71 consecutive patients with adrenal lesions 
were prospectively screened for hypercortisolism by dexamethasone suppression test (NCT 02611258). Complete 
anthropometric, metabolic and hormonal parameters were recorded along with full cardiac ultrasound assessment 
and noninvasive measurement of arterial stiffness. All patients underwent chemical-shift magnetic resonance imaging 
to characterize the lesions. Cardiovascular outcomes were recorded in blind.
Results: According to post-dexamethasone suppression cortisol values (post-DST), 34 patients had pACS and 37 non-
functioning adenomas (NFA). The two groups were similar in sex, BMI, age distribution, cardiovascular risk factors 
and comorbidities. Left ventricular mass index (LVMIBSA) was increased in pACS compared to NFA (P = 0.006) and mildly 
correlated to the post-DST cortisol level (rho = 0.347; P = 0.004). The post-DST cortisol levels explained up to 13.7% of 
LVMIBSA variance (P = 0.002). Compared to NFA, patients with pACS had a higher prevalence of diastolic dysfunction 
(35.1% vs 82.6%; P = 0.001) and worse arterial stiffness assessed by pulse wave velocity (P = 0.033).
Conclusions: In apparently asymptomatic patients, mild autonomous cortisol secretion can sustain early cardiac and 
vascular remodeling, independently of other risk factors. The morphological and functional cardiovascular changes 
observed in pACS underline the need for further studies to correctly define the long-term management of this 
relatively common condition.
Introduction
Adrenal incidentalomas are clinically silent masses 
discovered inadvertently during diagnostic imaging 
procedures performed for unrelated reasons. Depending 
on the criteria applied, up to 50% of patients with 
adrenal incidentalomas may have biochemical evidence 
of cortisol excess (1, 2). Possible autonomous cortisol 
secretion (pACS), as recently defined in the European 
Society of Endocrinology Guidelines, is characterized by 
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a partial, incomplete suppression of the hypothalamic–
pituitary–adrenal (HPA) axis without the typical signs 
of overt cortisol hypersecretion (i.e. moon face, truncal 
obesity, easy bruising, thin extremities, proximal 
myopathy, cutaneous purple striae) (2). It is widely 
recognized that overt endogenous hypercortisolism 
(Cushing’s syndrome CS) is associated with excessive 
mortality, mainly due to cardiovascular (CV) disease (3). 
However, the mechanism leading to cardiac damaging 
remains unclear (3, 4). For this reason, the ERGO trial 
(Endocrine Cardiomyopathy in Cushing Syndrome: 
Response to Cyclic GMP PDE5 inhibitOrs) was designed. 
Retrospective analysis unexpectedly revealed that also 
asymptomatic patients with adrenal adenomas and 
low-grade autonomous cortisol secretion suffer from 
a higher rate of CV events and mortality than patients 
with normal HPA axis suppression (5, 6, 7). Despite these 
epidemiological associations, only two small studies 
investigated morphological and functional changes to 
the CV system in patients with mild hypercortisolism 
(8, 9). In particular, they did not investigate whether 
CV changes correlated to cortisol levels. The fact that 
pACS is, by definition, asymptomatic prompted us to 
investigate the cardiac features of these patients, taking 
advantage of patients screened during enrollment for the 
ERGO trial. All patients with pACS underwent a complete 
ultrasound assessment of structural and functional left 
ventricular (LV) abnormalities accompanied, for the first 
time, by arterial stiffness assessment. Patients were then 
stratified according to response to the dexamethasone 
suppression test. The main hypothesis of this sub-analysis 
of the ERGO trial was to test whether left ventricular mass 
index (LVMI) is higher in pACS than in nonfunctioning 
adenoma (NFA) patients.
Subjects and methods
Protocol
109 consecutive outpatients aged between 18 and 75 years 
with an incidentally detected adrenal mass were screened 
for inclusion in the ERGO trial (NCT02611258). The main 
inclusion criterion to enter the ERGO trial is a diagnosis 
of CS. The study population of the current sub-analysis 
consists of all screened patients with an adrenal lesion 
not matching a diagnosis of CS (Fig. 1). All patients were 
evaluated at the Department of Experimental Medicine, 
Sapienza, University of Rome between July 2016 and 
September 2017.
All patients were clinically examined and evaluated for 
signs and symptoms typical of adrenal hormones excess. 
Anthropometric measurements were assessed by the same 
person. BMI was calculated by dividing weight (in kg) 
by height (in m2). Arterial hypertension was defined as 
systolic blood pressure (SBP) ≥140 mmHg and/or diastolic 
blood pressure (DBP) ≥90 mmHg on repeated evaluations 
and/or reported use of antihypertensive medication (10). 
Type 2 diabetes mellitus (T2DM) was diagnosed according 
to ESC guidelines or reported use of antidiabetic drugs 
(11). Dyslipidemia was diagnosed according to ESC/
EAS Guidelines or reported use of hypolipidemic drugs 
(12). Current smokers were patients who smoked any 
tobacco during the observation period or patients who 
had smoked in the last twenty years. The study was 
performed following Declaration of Helsinki principles 
and the protocol approved by the Ethics Committee of 
‘Sapienza’ University of Rome on the 19 November 2015 
with reference number 3875, and subsequently registered 
on NIH (NCT02611258). An informed consent has been 
obtained from each patient.
Biochemical and radiological evaluation
Fasting baseline sampling was performed for measurement 
of blood glucose, insulin, glycated hemoglobin, sodium, 
potassium, creatinine, total cholesterol, HDL cholesterol 
and triglycerides. Insulin resistance was assessed using 
HOMA-IR.
The functional status of incidentally discovered adrenal 
masses was determined according to the ESE 2016 guide-
lines (2). Blood tests included an endocrine workup taken 
after an overnight fast and performed between 08:00 h 
and 09:00 h. Baseline cortisol (radioimmunoassay), ACTH 
(immunoradiometric assay), dehydroepiandrosterone 
sulfate (DHEAS) (chemiluminescence), androstenedione 
(radioimmunoassay), 17OH-progesterone (radioimmuno-
assay) and aldosterone/renin ratio (radioimmunoassay) 
were measured in all patients. Urinary free cortisol (UFC) 
(radioimmunoassay) and 24-h urine metanephrine (radio-
immunoassay) tests were also performed.
 Adrenal lesions were discovered by abdominal 
ultrasonography, CT scan or MRI and confirmed in all 
cases with chemical shift MRI. All adrenal masses were 
larger than 10 mm and showed a MRI pattern consistent 
with benign adenoma (i.e. regular margins, loss of signal 
intensity on out-of phase images compared with in-phase 
images, size <6 cm).
Of the 109 patients with adrenal incidentalomas , 
those with overt Cushing’s syndrome, pheocromocytoma, 
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Conn syndrome, adrenocortical carcinoma, late-onset 
congenital adrenal hyperplasia, myelolipoma, adrenal 
metastasis and adrenal hemorrhage were not included 
in the current analysis. Patients taking medications 
influencing glucocorticoid production or metabolism, 
patients with psychiatric diseases or alcohol abuse, 
myocardial infarction or unstable angina, history of 
malignancy, infections and infiltrative diseases potentially 
affecting the adrenal glands were also excluded. This left a 
group of 71 patients (Fig. 1).
Interpretation of the results of the 1 mg overnight 
dexamethasone test (1 mg-DST) was based on the 2016 
European Society of Endocrinology guidelines (2). 
1 mg-DST cortisol levels between 51 and 138 nmol/L were 
considered as possible autonomous cortisol secretion 
(pACS) and greater than 138 nmol/L were considered as 
Cushing’s syndrome sustained by autonomous cortisol 
secretion. 1 mg-DST cortisol levels below 50 nmol/L were 
considered to identify patients with nonfunctioning 
adenoma (NFA). Since the 1 mg-DST has the same 
sensitivity (98%) but lower specificity than the classic 
2-day 2-mg Liddle test (2 mg-DST) (87.5 vs 97–100%) (13), 
in all patients with 1 mg-DST cortisol above 50 nmol/L, 
the test was confirmed by 2 mg-DST. In the final data 
set analysis, the cortisol values for patients with normal 
suppression on 1 mg-DST and the 2 mg-DST values for all 
remaining patients were combined (post-DST).
Cardiovascular evaluation
Transthoracic echocardiography was performed by a 
blinded outcome assessor using an Aplio CV Toshiba 
with a 3 MHz transducer in 2D, Doppler, color-Doppler 
and Tissue Doppler Imaging (TDI). Patients were 
examined in the left lateral decubitus position according 
to the American Society of Echocardiography guidelines 
(14). Left ventricle end-diastolic diameter (LVED), 
interventricular septal thickness (IVS) and posterior wall 
thickness (PWT) were measured at end diastole. Left 
ventricular mass (LVM) was calculated by the corrected 
American Society of Echocardiography method: LVM = 0.8 
(1.04 ((LVED + IVS + PWT)3–(LVED)3) + 0.6). LVM index 
(LVMIBSA) was calculated as LVM divided by body surface 
area (BSA). LV hypertrophy was defined according to 
gender-specific criteria as 2D measurements greater than 
88 g/m2 in women and 102 g/m2 in men. The relative wall 
1-mg overnight 
dexamethasone 
suppression test n=71 
Cortisol suppressed ( 50 nmol/L)  
n=34
Consecutive patients with 
incidentally detected 
adrenal masses  
n=109
Overtly active or malignant adrenal tumor n=21 
CS (ERGO Study), PHEO, Conn Syndrome, AC, late-onset CAH, 
myelolipoma, adrenal metastasis, adrenal hemorrhage
Cortisol not suppressed (>50 nmol/L)  
n=37
2-day 2-mg Liddle test  
Cortisol suppressed ( 50 nmol/L) 
n=3 
Cortisol not suppressed (51-138 nmol/L)
n=34 
Possible autonomous cortisol secretion 
(pACS) n=34 
Non-functioning adenomas  
(NFAs) n=37  
Failed inclusion criteria n=17  
Patients taking medications affecting glucocorticoid production or 
metabolism, patients with psychiatric diseases or alcohol abuse, 
myocardial infarction or unstable angina 
Cortisol >138 nmol/L 
(n=0) 
Figure 1
Study flow diagram. AC, adrenal carcinoma; CAH, congenital adrenal hyperplasia; CS, Cushing syndrome; NFA, non-functioning 
adenoma; PHEO, pheochromocytoma; pACS, possible autonomous cortisol secretion.
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thickness (RWT) was calculated as (IVS + PWT)/LVED. 
RWT > 0.42 was considered pathologic. Patients with 
increased LVMIBSA and increased RWT were considered 
to have concentric LV hypertrophy, while those with 
increased LVMIBSA and normal RWT were considered to 
have eccentric LV hypertrophy. LVMIBSA is widely used in 
routine practice, and it has been documented to detect 
hypertension-related cardiac hypertrophy. We also 
calculated LVM normalized to height2.7 to obtain LVMIh2.7, 
which is considered to be more sensitive in detecting 
obesity-related LVH (15).
Left atrial (LA) anteroposterior size was assessed in the 
parasternal long axis. Left ventricular ejection fraction 
(LVEF) was determined by manual tracing using Simpson’s 
biplane method.
Left ventricular diastolic dysfunction (LVDD) was 
assessed by pulse-wave Doppler evaluating the following 
parameters: early-E-wave (E) and late A-wave (A) diastolic 
filling velocities and E/A ratio. TDI measurements were 
performed in the apical 4-chamber view and the sample 
volume was placed in the septal mitral annulus and lateral 
mitral annulus. Early diastolic tissue velocities (E’) from both 
the septal (E’s) and lateral (E’l) wall were assessed and mean 
E’ (E’m) was calculated; E/E’ ratio was derived, reflecting the 
LV filling pressures. LVDD was diagnosed on the basis of 
E’s < 8 cm/s or E’l < 10 cm/s. Diastolic dysfunction (grade I, 
mild; grade II, moderate or grade III, severe) was quantified 
using EAE recommendations (16). Right ventricular 
function was assessed as the tricuspid annular plane systolic 
excursion (TAPSE). TAPSE < 17 mm is highly suggestive of 
RV (right ventricular) systolic dysfunction.
Blood pressure and arterial stiffness 
Arterial stiffness and blood pressure (BP) were assessed by 
BPLab (Vasotens Technology), using brachial oscillometric 
blood pressure waves for a noninvasive estimation. The 
measurements were performed in the supine position after 
the patients had been resting for a minimum of 5 min. The 
distance from the jugulum to the symphysis was measured 
in every patient. The optimal adult cuff was wrapped 
around the non-dominant arm. In a single session 
measurements of brachial systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) were taken three times, 
at 5-min interval. Their average was used for analyses. 
During the BP measurement the pressure waveforms in the 
cuff were registered and digitalized. Thereafter, an aortic 
pulse wave was generated to derive the aortic pressure 
wave. The difference in time between the beginning of 
the first wave and the beginning of the second (reflected 
wave) was related to the distance from the jugulum 
to the symphysis, resulting in the pulse-wave velocity 
(PWV) in m/s. Therefore, PWV and reflected wave transit 
time (RWTT), which have been used to evaluate arterial 
stiffness, were obtained after the end of measurement.
Statistical analysis
Based on previously published data (17) describing 
25 g/m2 standard deviation (s.d.) for LVMIBSA in the 
population with hypercortisolism, and considering 
cautiously 20 g/m2 as the minimal clinically relevant 
difference between groups, a calculated sample size of 54 
would have provided 90% power to detect the specified 
minimum detectable difference in LVMIBSA at a 2-sided 
significance level of 0.05.
Distribution of continuous variables was tested 
with the Shapiro–Wilk test; linearity was established by 
visual inspection of a scatterplot. Categorical variables 
were expressed as percentage and frequency; continuous 
variables were reported as mean and 95% confidence 
interval (95% CI) or median and interquartile range 
(25th–75th percentile). For group comparisons unpaired 
Student’s T-test, Mann–Whitney, χ2 or Fisher’s exact test 
were used as appropriate. A general linear model including 
the presence or absence of autonomous cortisol secretion 
as a fixed effect and factors known to affect cardiovascular 
features as covariates was developed. In the analysis 
of covariance (ANCOVA) model, log transformation 
or reciprocal transformation were used for skewed 
data. Regression analysis was performed to estimate 
the contributors to LVMIBSA variability. Standardized 
residuals were tested for normality. Homoscedasticity 
and homogeneity of variances were assessed by visual 
inspection. Multicollinearity was assessed by calculation 
of the variance inflation factor (VIF). Sensitivity analysis 
was performed excluding both patients with a diagnosis 
of diabetes mellitus and those with discrepancies between 
the two suppression tests. Correlations between parameters 
were analyzed using Pearson and Spearman’s correlation 
coefficients. A P < 0.05 was considered statistically 
significant. All statistical analyses were performed using 
SPSS software (Version 19.0; IBM, Normal).
Results
Clinical and biochemical evaluation
A total of 109 patients with incidentally discovered adrenal 
mass were screened in the ERGO trial, of whom 38 did 
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not meet the inclusion criteria for the current analysis. 
The remaining 71 patients with AI fulfilling the inclusion 
criteria were enrolled (Fig. 1). Of these, 37 had 1 mg-DST 
serum cortisol levels greater than 50 nmol/L and underwent 
confirmatory 2 mg-DST, giving rise to a diagnosis of pACS 
in 34. The remaining three cases (1 mg-DST serum cortisol 
levels respectively 180, 92.8, 69.1 nmol/L) were found to 
be false positives, with complete suppression on 2 mg-DST 
(respectively 27.6, 46.9, 33.5 nmol/L). Of the four patients 
with 1 mg-DST above 138 nmol/L (respectively 181, 180, 
161, 147 nmol/L), none had a 2 mg-DST higher than 
138 nmol/L (respectively 135, 27.6, 131, 134 nmol/L). In 
all, therefore, 37 patients had a post-DST cortisol level 
below 50 nmol/L and were defined as NFA (Fig. 1).
Table  1 describes the clinical and biochemical 
characteristics of all patients with AI, divided into pACS 
and NFA. The two groups were similar for sex, BMI and 
age distribution. There was no statistically significant 
difference in blood glucose, insulin, insulin resistance, 
glycated hemoglobin, sodium, potassium, creatinine, 
total cholesterol, HDL-cholesterol or triglycerides 
between the groups. Cardiovascular risk factors and 
comorbidities (arterial hypertension, dyslipidemia, 
smoking) were equally distributed among NFA and pACS, 
as were duration of hypertension and the number of 
antihypertensive, antidiabetic and hypolipidemic drugs 
(Table 1). The relative prevalence of T2DM was apparently 
higher in the pACS compared to NFA, although this was 
not statistically significant due to the small number of 
patients in each group.
The diameter of the lesions was higher in pACS than 
NFA patients (27.4 (95% CI: 23–32) vs 20.2 mm (95% CI: 
17–23); P = 0.004) and positively correlated with post-
DST cortisol levels (rho = 0.441; P < 0.001). Hormone 
parameters are shown in Table 2. pACS had lower ACTH 
(18 (95% CI: 15–20) vs 25 (95% CI: 19–31) pg/mL; 
P = 0.028) and DHEAS (37.4 (18–54) vs 78 (45–189) μg/dL; 
P = 0.012) levels compared to NFA patients. No correlation 
was found between age and post-DST cortisol levels 
(rho = 0.123; P = 0.32).
Table 1 Clinical and biochemical characteristics of all enrolled subjects.
Adrenal incidentalomas (n = 71) NFA (n = 37) pACS (n = 34) P§,*,#
Age (years)* 67 (59–72) 67 (60–72) 68 (57–73) 0.161
Male/Female gender 24/47 11/26 13/21 0.449
Body mass index (kg/m2)* 26.3 (23.5–29.4) 25.9 (23.7–31.2) 26.7 (22.6–29.3) 0.275
Overweight patients+ 30/71 (42.3%) 15/37 (40.5%) 15/34 (44.1%) 0.761
Obese patients+ 17/71 (23.9%) 7/37 (18.9%) 10/34 (29.4%) 0.301
Diameter of adenoma (mm)§ 23.8 (21.2–26.4) 20.2 (17.2–23.1) 27.4 (23.4–31.5) 0.004
Blood glucose (mg/dL)* 92 (85–105) 90 (85–96) 94 (85–110) 0.475
Glycated hemoglobin (%)* 5.5 (5.2–5.7) 5.5 (5.3–5.7) 5.5 (5.2–5.7) 0.294
Insulin (µU/mL)* 8.7 (6.9–10) 8.6 (6.6–10.4) 8.7 (7.3–10) 0.850
HOMA-IR Index* 2 (1.5–2.4) 1.9 (1.4–2.4) 2 (1.5–2.5) 0.917
Total cholesterol (mg/dL)§ 205 (197–212) 199 (187–210) 212 (201–220) 0.114
LDL cholesterol (mg/dL)§ 121 (113–130) 114 (102–126) 130 (116–141) 0.089
HDL cholesterol (mg/dL)* 62 (54–71) 59 (53–67) 63 (54–72) 0.510
Triglycerides (mg/dL)* 90 (75–119) 104 (83–131) 90 (73–122) 0.550
Creatinine (mg/dL)* 0.7 (0.7–0.8) 0.7 (0.7–0.8) 0.7 (0.7–0.8) 0.217
Sodium (mmol/L)§ 142 (141–143) 142 (141–143) 142 (140–143) 0.765
Potassium (mmol/L)§ 4.3 (4.2–4.4) 4.2 (4–4.3) 4.3 (4.2–4.5) 0.146
Hypertension+ 45/71 (63.4%) 23/37 (62.2%) 22/34 (64.7%) 0.824
Number of antihypertensive drugs+ 0.463
  1–2 30/45 (66.7%) 17/23(73.9%) 13/22 (59.1%)
  3–4 15/45 (33.3%) 6/23 (26.1%) 9/22 (40.9%)
Duration of hypertension# 0.488
  <10 years 21/45 (46.7%) 10/23 (43.5%) 11/22 (50%)
  10–20 years 16/45 (35.5%) 10/23 (43.5%) 6/22 (27.3%)
  >20 years 8/45 (17.8%) 3/23 (13%) 5/22 (22.7%)
Type 2 diabetes mellitus# 9/71 (12.7%) 2/37 (5.4%) 7/34 (20.6%) 0.077
Taking antidiabetic drugs+ 8/9 (88.9%) 1/2 (50%) 7/7(100%) 0.222
Dyslipidemia+ 45/71 (63.4%) 21/37 (56.8%) 24/34 (70.6%) 0.227
Taking hypolipidemic drugs+ 14/45 (31.1%) 6/21 (28.6%) 8/24 (33.3%) 0.371
Smoker+ 24/71 (33.8%) 13/37 (35.1%) 11/34 (32.4%) 0.804
Categorical variables are expressed as frequency and percentages. Continuous variables are expressed as §mean (95% CI) or *median (25th–75th 
percentile).
§Unpaired sample T-test or *Mann–Whitney test and #χ2 or Fisher’s exact test, as appropriate.
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Echocardiographic findings
Morphological analysis showed that both LVMIBSA and 
LVMIh2.7 were significantly higher in the pACS than NFA 
group (LVMIBSA: 90.25 (71.7–110.3) vs 76.6 (64–85) g/m2; 
P = 0.006; LVMIh2.7: 46.3 (33.6–54.6) vs 34.7 (30–41) g/m2.7; 
P = 0.003). Two linear models were developed adjusting 
for known contributors of LVMIBSA. The first model 
included age and BMI  and the second age, BMI, HbA1c, 
LDL cholesterol and SBP (Table  3). Estimated marginal 
means of the main CV outcomes are given in Table  3. 
After adjusting for all covariates a statistically significant 
difference in LVMIBSA and LVMIh2.7 was still found between 
the two groups (P = 0.001). There was also a significantly 
higher prevalence of LV hypertrophy in the pACS than 
the NFA group (53% vs 13.5%; P = 0.001), including both 
concentric LV hypertrophy (26.5% vs 5.4%) (P = 0.014) 
and eccentric LV hypertrophy (26.5% vs 8.1%) (P = 0.039). 
LVMIBSA and LVMIh2.7 were both positively correlated to 
post-DST cortisol (rho = 0.347, P = 0.004 and rho = 0.336, 
P = 0.005, respectively Fig. 2).
A regression model was used to estimate the contributors 
to LVMIBSA in patients with adrenal incidentalomas. The 
model included age, BMI, SBP, Hba1C, LDL cholesterol 
and post-DST cortisol. Step-wise post-DST cortisol, SBP 
and Hba1C were the only independent determinants of 
LVMIBSA explaining up to 31.7% of LVMIBSA. Specifically, 
the post-DST cortisol level was the main independent 
contributor to LVMIBSA (P = 0.002), accounting for 13.7% 
of LVMIBSA variability, followed by SBP (9.9%) and Hba1C 
(8.1%). No collinearity between SBP and post-DST cortisol 
was found (VIF = 1), suggesting an independent effect of 
cortisol on cardiac function.
Interventricular septal thickness (IST) was greater in 
the pACS than in the NFA group (10.8 (95% CI: 9.9–11.8) 
vs 9.9 (95% CI: 9.3–10.3); P = 0.015). LVEF was similar 
between the two groups (63.2 (95% CI: 61.2–65.9) vs 62.8 
(95% CI: 59.9–64.5); P = 0.786). Mean TAPSE values were 
significantly lower in the pACS than in the NFA group 
(19.9 (95% CI: 18.5–21.3) vs 22.1 (95% CI: 20.9–23.4); 
P = 0.046).
Functional analysis showed a higher prevalence of 
LVDD in patients with pACS (82.3% vs 35.1%; P = 0.001). 
pACS patients, compared with NFA group, had lower 
septal E’ (7.3 (95% CI: 6.5–8.0) vs 8.61 (95% CI: 7.7–9.5) 
cm/s; P = 0.027), lower E’m (8.24 (95% CI: 7.6–8.9) vs 9.57 
(95% CI: 8.6–10.5); P = 0.024) and higher E/e’m (8.99 (95% 
CI: 8–10) vs 7.38 (95% CI: 6.6–8.1) cm/s; P = 0.010). The 
severity of diastolic dysfunction in pACS patients appeared 
worse than that in the NFA group (Grade I: 38.2% vs 27%; 
Grade II: 35.3% vs 8.1%; Grade III: 8.8% vs 0%).
To exclude that an odd distribution of T2DM 
prevalence among the two groups might explain some 
of the observed differences in the CV assessment, a 
sensitivity analysis was performed excluding both 
patients with T2DM and those with discrepant findings 
on 1-mg  DST vs 2-mg  DST. This produced similar 
findings for LVMIBSA and diastolic dysfunction (Table 4), 
confirming the validity of the dataset. To rule out an 
influence of glycemic control, HbA1c was also included 
in the regression models.
Arterial stiffness
RWTT was significantly lower (123.5 (113–129) vs 129.5 
(121–135) m/s; P = 0.048), whereas PWV was significantly 
higher (11.05 (95% CI: 10.4–11.7) vs 10.3 (95% CI: 9.9–
10.6) m/s; P = 0.033), in the pACS compared to the NFA 
group. After adjusting for age and BMI, a significant 
difference in PWV was found between the two groups 
(P = 0.040, Table 3).
Table 2 Hormonal parameters.
Adrenal incidentalomas (n = 71) NFA (n = 37) pACS (n = 34) P§,*
Baseline cortisol (nmol/L)§ 493 (434–537) 470 (372–512) 517 (445–600) 0.244
ACTH (pg/mL)§ 22 (18–25) 25 (19–31) 18 (15–20) 0.028
Aldosterone/renin ratio* 30 (20–39) 29 (21–37) 31 (19–64) 0.084
17OH progesterone (ng/mL)* 0.5 (0.3–0.9) 0.6 (0.3–0.9) 0.6 (0.4–0.8) 0.773
DHEAS (µg/dL)* 48 (24–88) 77.8 (45–189) 37.5 (18–54) 0.012
Urinary free cortisol (nmol/24 h)* 121 (97–184) 110 (81–167) 145 (106–202) 0.708
Androstenedione (ng/dL)* 97 (84–172) 109 (87–173) 89 (63–178) 0.613
Urine metanephrine (µg/24 h)* 58 (41–87) 57 (40–96) 75 (41–87) 0.685
1 mg-DST cortisol (nmol/L)* 58 (42–77) 41.4 (34.2–49.0) 76.3 (62–93) 0.001
Post-DST cortisol (nmoL/L)* 54 (42–77) 41.4 (34.2–48.6) 73.4 (57–90) 0.001
Continuous variable are expressed as §mean (95% CI) or *median (25th–75th percentile).
§Unpaired sample T-test or *Mann–Whitney test as appropriate.
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Discussion
Our findings suggest that exposure to mild levels of 
autonomous cortisol secretion sustains structural and 
functional changes of the LV and medium-sized vessel 
arterial wall that may account for the observed increase 
in CV events and related mortality described in other 
studies.
In our cohort of patients with AI, both mean LVMI 
and prevalence of LV hypertrophy was higher in pACS 
than in NFA patients. LVMI is a sensitive indicator of 
cardiac end-organ damage and an independent risk factor 
for the development of heart failure. LV hypertrophy 
is the hallmark of several detrimental cardiovascular 
diseases and is associated with a worse prognosis 
after cardiac events (18). We also find a mild positive 
Table 3 Cardiac and arterial stiffness features comparisons between groups.
NFA (n = 37) pACS (n = 34) P value
ANCOVA modela
  Echocardiographic measurements
  LV end-diastolic diameter (mm) 45.6 (43.9–47.2) 47.1 (45.5–48.8) 0.194
  IST (mm) 10.0 (9.5–10.5) 10.7 (10.2–11.3) 0.042
  Posterior wall thickness (mm) 8.4 (7.9–8.9) 9.1 (8.6–9.6) 0.071
  Relative wall thickness 0.41 (0.39–0.43) 0.42 (0.4–0.45) 0.279
  LV mass (g) 141 (127–166) 168 (153–182) 0.014
  LV massBSA (g/m2) 77.0 (70–85) 92.8 (85.5–100.2) 0.009
  LV massh2.7 (g/m2.7) 37.3 (33.5–40.9) 44.9 (41.3–48.7) 0.004
  Left atrial size (mm) 36.2 (34.6–37.8) 36.3 (34.6–37.9) 0.955
  LV ejection fraction (%) 63.1 (60.9–65.3) 60.7 (60.7–65.0) 0.850
  E/A 0.9 (0.8–1.1) 1.0 (0.8–1.2) 0.530
  E’l (cm/s) 10.3 (9.3–11.3) 9.5 (8.5–10.3) 0.211
  E’s (cm/s) 8.5 (7.7–9.2) 7.5 (6.7–8.2) 0.093
  E’m (cm/s) 9.4 (8.6–10.2) 8.4 (7.7–9.2) 0.065
  E/e’ l 7.0 (6.2–7.9) 7.9 (7.1–8.8) 0.155
  E/e’s 8.6 (7.5–9.6) 10.2 (9.1–11.3) 0.044
  E/e’ m 7.6 (6.8–8.3) 8.7 (7.9–9.6) 0.061
  TAPSE (mm) 21.9 (20.8–23.1) 20.3 (18.9–21.5) 0.064
  Arterial stiffness measurements
  Systolic blood pressure (mmHg) 137.2 (131.1–143.4) 136.8 (131.1–142.9) 0.917
  Diastolic blood pressure (mmHg) 83.3 (79.3–87.2) 83.1 (79.2–86.9) 0.946
  Mean blood pressure (mmHg) 110.3 (106–115) 109.9 (106–114) 0.918
  Heart rate (bpm) 69.9 (65.1–74.7) 76.6 (71.1–82.1) 0.143
  Reflected wave transit time (m/s) 127.5 (123–132) 120.6 (115.9–125.3) 0.031
  Pulse-wave velocity (m/s) 10.3 (9.9–10.8) 11.0 (10.5–11.5) 0.040
ANCOVA modelb
  Echocardiographic measurements
  LV end-diastolic diameter (mm) 45.6 (44.0–47.3) 47.3 (45.5–49.0) 0.198
  IST (mm) 9.9 (9.4–10.4) 10.7 (10.2–11.2) 0.015
  Posterior wall thickness (mm) 8.4 (7.9–9) 9.1 (8.5–9.6) 0.047
  Relative wall thickness 0.40 (0.39–0.4) 0.42 (0.39–0.43) 0.193
  LV mass (g) 140 (126–155) 169 (154–184) 0.013
  LV massBSA (g/m2) 76.6 (69.6–83.6) 95.3 (88.0–102.5) 0.001
  LV massh2.7 (g/m2.7) 36.2 (32.8–39.6) 46.1 (42.5–49.6) 0.001
  Left atrial size (mm) 35.5 (34.1–36.9) 35.9 (34.3–37.5) 0.685
  LV ejection fraction (%) 63.4 (61.09–65.7) 62.7 (60.4–65.1) 0.692
  E/A 0.9 (0.79–1.0) 0.9 (0.8–1.1) 0.524
  E’l (cm/s) 10.4 (9.3–11.5) 9.3 (8.1–10.5) 0.199
  E’s (cm/s) 8.5 (7.7–9.3) 7.4 (6.4–8.2) 0.059
  E’m (cm/s) 9.4 (8.6–10.2) 8.3 (7.4–9.2) 0.067
  E/e’ l 6.8 (5.9–7.8) 8.0 (6.9–9.1) 0.125
  E/e’s 8.3 (7.2–9.5) 10.3 (9.0–11.6) 0.028
  E/e’ m 7.4 (6.6–8.3) 8.85 (7.8–9.8) 0.044
  TAPSE (mm) 22.2 (21.1–23.3) 20.2 (18.9–21.6) 0.036
a,bANCOVA models for group comparisons with possible autonomous cortisol secretion (pACS) as fixed factor and the following as covariates: modela, 
age and BMI; modelb, age, BMI, SBP, LDL cholesterol and Hba1C. Values represent the estimated marginal means (lower-upper limit of 95% CI).
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correlation between both LVMIBSA and LVMIh2.7 and 
post-DST cortisol. For the first time, we documented a 
diastolic dysfunction associated with pACS. The presence 
of LVDD is considered an independent risk factor for 
heart failure and death from cardiac causes. LVDD is 
also associated with a reduced quality of life (19, 20). 
TAPSE has been proposed as a simple and reproducible 
parameter for qualitative RV systolic function. We found 
a mild reduction of TAPSE in pACS compared to NFA 
patients. Although TAPSE may slightly overestimate or 
underestimate RV function because of cardiac translation, 
it still correlates well with the parameters estimating RV 
global systolic function (14).
Arterial stiffness analysis showed that patients with 
pACS had significantly higher PWV and lower RWTT. 
PWV is the most validated method for the noninvasive 
quantification of arterial stiffness and is considered 
the gold standard index (21). Increased PWV, and thus 
arterial stiffness, has been associated with increased 
morbidity and cardiovascular mortality and is considered 
an independent early predictor of coronary heart disease 
and stroke in the general population (22). In our study, 
compared to NFA patients, pACS patients presented a 
worse metabolic profile, although this difference was not 
statistically significant. There was no significant difference 
between the two groups in age, gender distribution, BMI, 
arterial hypertension, T2DM, dyslipidemia and smoking 
habit, all important parameters associated with increased 
cardiovascular risk; therefore, these were reasonably 
excluded as possible confounders. The two groups also 
showed similar duration of arterial hypertension and 
number of antihypertensive drugs.
Cortisol is thought to have direct relevant effects on 
cardiac function: it potentiates cardiac angiotensin II and 
noradrenaline responsiveness and also stimulates the 
local renin-angiotensin system (4). Complex mechanisms 
including endothelial damage, activation of inflammation, 
increased oxidative stress and fibroproliferation are 
correlated with high cortisol levels, leading to functional 
and structural change in the heart and blood vessels. An 
increased prevalence of LV hypertrophy and LV diastolic 
dysfunction (albeit with preserved LV ejection fraction) 
Figure 2
Correlation between post-DST cortisol 
levels and left ventricular mass index 
normalized to BSA (LVMIBSA) (A) and 
normalized to height2.7 (LVMIh2.7) (B).
Table 4 Sensitivity analysis of cardiac and arterial stiffness excluding patients with of diabetes mellitus or discrepancies between 
the 1 mg DST and 2-mg DST.
Adrenal incidentalomas (n = 59) NFA (n = 32) pACS (n = 27) P§,*,+
Pulse-wave velocity (m/s)§ 10.6 (10.2–11) 10.3 (9.9–10.7) 11.0 (10.3–11.7) 0.039
LV massBSA (g/m2)* 76.1 (64.3–86) 75.9 (63.4–80.1) 83.8 (64.7–105.5) 0.032
LV massh2.7 (g/m2.7)* 34.1 (30.7–41) 33.2 (30.1–36.6) 37.4 (31.1–48.8) 0.022
LV hypertrophy+ 19/59 (32.2%) 5/32 (15.6%) 14/27 (51.8%) 0.003
E’s (cm/s)§ 8.0 (7.3–8.7) 8.6 (7.6–9.5) 7.3 (6.4–8.2) 0.039
E’m (cm/s)§ 9.1 (8.4–9.8) 9.7 (8.7–10.8) 8.3 (7.6–9.1) 0.022
E/e’l§ 7.0 (6.3–7.7) 6.3 (5.6–7.1) 7.8 (6.7–8.9) 0.029
E/e’s§ 9.0 (8.1–9.9) 8.0 (5.6–7.1) 10.2 (8.6–11.7) 0.021
E/e’ m§ 7.7 (7.1–8.4) 7.0 (6.2–7.7) 8.6 (7.6–9.6) 0.011
Diastolic dysfunction+ 33/59 (55.9%) 10/32 (31.25%) 23/27 (85.2%) 0.001
Continuous variable are expressed as §mean (lower-upper limit of 95% CI) or *median (25th–75th percentile). Categorical variables are expressed as 
frequency and percentages.
§Unpaired sample T-test or *Mann–Whitney test and +X-square as appropriate.
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are consistently found in Cushing’s syndrome (CS). In 
patients with CS, systolic and diastolic dysfunction can 
develop independently of the presence of hypertension 
(17, 23, 24, 25). We found a higher prevalence of LV 
hypertrophy in pACS than that reported in overt CS 
by previous echocardiography-based studies, where LV 
hypertrophy was found in 24–42% of affected patients 
(23, 25, 26, 27). However, cardiac hypertrophy increases 
with age, and in those studies on CS (23, 25, 26, 27) the 
mean age was significantly lower than in our cohort of 
pACS patients (39–41 vs 65 years). Finally, a recent report 
on arterial stiffness in CS reported structural changes 
in the arterial wall occurring independently of blood 
pressure levels (28).
Recent studies suggest that even patients lacking 
the full clinical picture of CS having an adrenal 
incidentaloma and a non-suppressed cortisol after DST 
suffer from increased cardiovascular events and mortality 
when compared to NFA (5, 7, 29, 30). To our knowledge, 
this is the first study evaluating the relationship between 
pACS, LV function and structure and arterial stiffness 
and the first to describe a dose–response relationship 
between post-DST cortisol and LVMI. Only two previous 
studies presented data about echocardiographic findings 
of subclinical hypercortisolism. However, both were 
completed before the publication of the 2016 ESE 
Guidelines defining pACS (2). In 2013, Iacobellis and 
coworkers reported echocardiographic data on 6 patients 
with mild CS compared with 40 patients with NFA. In 
this study, mild CS was defined by two positive tests 
among UFC >70 µg per 24 h, post-DST serum cortisol 
levels >138 nmol/L (5 µg/dL) or ACTH levels <10 pg/mL. 
Patients matching these criteria had a higher LVM 
than those without (8). In 2015, Evran and coworkwers 
described the US findings of 5 patients with ‘subclinical 
Cushing’s syndrome’ defined as a post-DST cortisol 
values >50 nmol/L (1.8 µg/dL) and ACTH < 10 pg/mL. No 
echocardiographic differences were found between the 
5 patients with ‘subclinical Cushing’s syndrome’ and a 
group of 76 patients without CS (9).
The strengths of the present study are the presence 
of a confirmatory test for the diagnosis of pACS, the 
balanced distribution between the two groups and its 
prospective design: all echocardiography and arterial 
stiffness measurements were performed by the same 
clinician blinded to the diagnosis of pACS or NFA (blinded 
outcome assessor).
However, the study also has a number of limitations. 
The size of the two groups, although significantly 
higher than in other published studies, is still low to 
provide definitive data. In addition, there was no control 
group (patients without adrenal adenoma). Moreover, 
2D-echocardiogram and BPlab are not the gold standard 
methods to assess cardiac hypertrophy and arterial 
stiffness. Cardiac MRI or aortic catheterization would 
have provided more definitive findings. However, they are 
more affordable, have good reproducibility and are often 
used in the clinical setting for population studies (14, 31, 
32), expanding the applicability of our findings. Finally, 
some recent reports suggested that patients with NFA 
may also carry an increased CV risk compared with the 
general population, thus our study may underestimate 
the magnitude of cardiac damage associated with pACS. 
Among the hypotheses proposed, there is the possibility 
that NFAs produce excess cortisol in a cyclic manner, or 
during stress, or release excess steroid precursors, such as 
deoxycorticosterone and corticosterone (6, 33, 34).
In conclusion, our study shows that possible 
autonomous cortisol secretion (pACS) can sustain early 
cardiac and vascular dysfunction even in asymptomatic 
patients. Our results suggest that the finding of post-DST 
cortisol levels above 50 nmol/L requires careful monitoring 
of cardiovascular risk and long-term evaluation in non-
operated patients. These results underline the need for 
further studies, including second line cardiovascular 
assessment, to correctly characterize the molecular 
mechanism or pathway through which mild autonomous 
secretion can induce cardiac damage.
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